Anavex Life Sciences Corp (AVXL)

[Talon38]

Seven, believe this is small potatoes in comparison with the sunk costs for the 2700 patient P3 which Biogen is conducting with Aducanumab. These huge trials conducted in over 200 locations in a number of countries have a tremendous level of momentum and I'm afraid Vounatsos has little control of this because they were approved by Biogen's BOD before he came onboard. These two trials will not read out before 2019/2020.

If ANAVEX 2-73 proves effective in the next year and 3-71 has an even brighter future in AD, IMHO Biogen will turn around midstream and make a play of some magnitude for 2-73. This will be especially true if they partner with us for M/S